Systematic Review: Ketamine for BPD, Depression, and Suicidality

Systematic Review Finds Insufficient Evidence for Ketamine in BPD

A systematic review published on October 7, 2026, critically evaluated the role of intravenous and intranasal ketamine in treating borderline personality disorder (BPD), comorbid depression, and suicidality. The review, accessible via OpenAlex, synthesized data from five studies—two randomized controlled trials (RCTs) and three cohort studies—encompassing a total of 81 participants with BPD and 31 with elevated borderline features. The key finding is that current evidence is insufficient to recommend ketamine as a treatment for BPD, depression, or suicidality in this population. This analysis is particularly significant because, to date, no medication has been approved for BPD, and treatment options for comorbid depression and suicidality remain limited.

Mechanisms, Study Designs, and Clinical Context

Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has demonstrated rapid-acting antidepressant effects in treatment-resistant depression and acute suicidality, leading to the approval of intranasal esketamine by the U.S. Food and Drug Administration (FDA) for these indications. However, its application in BPD is less clear. The systematic review included studies using both intravenous and intranasal racemic ketamine, but found substantial heterogeneity in study design, BPD diagnosis methods, dosing protocols, and outcome measures. Notably, most studies were not powered to detect efficacy specifically in BPD, and many included participants with only elevated borderline features rather than confirmed diagnoses.

Across the included studies, ketamine was generally well tolerated in supervised settings, with transient dissociation being the most commonly reported side effect. Some studies suggested short-term reductions in depressive symptoms or suicidal ideation, but these findings were inconsistent and limited by small sample sizes, lack of standardized outcome measures, and short follow-up periods. Importantly, evidence regarding improvement in core BPD symptoms—such as affective instability, impulsivity, and interpersonal dysfunction—was sparse or absent.

Policy and Research Implications

Current evidence does not support the clinical use of ketamine for BPD, depression, or suicidality in BPD patients outside of research settings. The review underscores the investigational status of ketamine for this population, emphasizing that further research is needed before clinical recommendations can be made. Regulatory agencies such as the FDA and the European Medicines Agency (EMA) have not approved ketamine for BPD, and the review's findings reinforce the need for caution among clinicians considering off-label use.

• Trial Design: The review calls for adequately powered, BPD-specific randomized trials with standardized diagnostic criteria, outcome measures, and longer follow-up periods.
• Research Gaps: The lack of BPD-specific efficacy data means that even observed benefits for depression or suicidality cannot be confidently generalized to BPD populations.
• Clinical Guidance: Until robust evidence emerges, ketamine should not be considered a standard or recommended treatment for BPD or its comorbidities.

A non-obvious implication highlighted by the review is that the heterogeneity in BPD diagnosis and outcome measures across existing studies may obscure true signals of efficacy or risk, suggesting that harmonization of trial protocols could accelerate progress more than simply increasing sample sizes.

Risks, Unknowns, and Safety Considerations

Ketamine appears generally well tolerated in short-term, supervised research settings, but the safety profile in BPD patients remains incompletely characterized. The most common adverse effect reported was transient dissociation, but the studies' short follow-up periods preclude assessment of longer-term risks such as misuse, dependency, or exacerbation of BPD symptoms. Furthermore, the review notes the possibility of differential treatment responses between individuals with and without borderline pathology, a factor not adequately addressed in current studies.

Another key unknown is the potential for ketamine to interact with the emotional dysregulation and impulsivity characteristic of BPD, which could pose unique safety challenges not seen in other populations. Without standardized, longer-term safety data, clinical use of ketamine in BPD remains speculative and potentially risky.

Looking Forward: Next Steps for Research and Practice

Future research on ketamine for BPD should prioritize large, well-controlled randomized trials targeting BPD as the primary diagnosis, with standardized diagnostic and outcome measures and extended follow-up. Collaboration between academic centers, regulatory agencies, and patient advocacy groups could help establish consensus protocols and facilitate data sharing. For now, ketamine use in BPD should remain within the context of clinical trials, with careful monitoring for both efficacy and safety.

Clinicians, researchers, and policymakers should be aware that while ketamine holds promise for some psychiatric conditions, its role in BPD remains unproven and investigational. The current evidence base does not justify off-label clinical use, and rigorous research is needed to clarify both benefits and risks for this complex and vulnerable population.

How we research: This article was written and reviewed by Dr. Jamie L. Carter, PhD (Clinical Psychology), on 2026-10-09. Primary source: OpenAlex systematic review W7220697877.